Understanding how actin mutations affect smooth muscle function in visceral myopathy

Biochemical and cellular mechanisms linking actin mutations to visceral myopathy

NIH-funded research Children's Hosp of Philadelphia · NIH-10910114

This study is looking at how changes in a specific protein can cause problems with bowel, bladder, and uterine muscle function, and it aims to find out how these changes affect symptoms so that doctors can create better, personalized treatments for people with visceral myopathy.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionChildren's Hosp of Philadelphia NIH-funded
Lab location1 site (Philadelphia, United States)
Project IDNIH-10910114 on NIH RePORTER

What this research studies

This research investigates the underlying mechanisms by which mutations in the actin protein lead to visceral myopathy, a condition that severely impacts bowel, bladder, and uterine smooth muscle function. The study aims to identify specific mutations in the ACTG2 gene and how they contribute to symptoms like chronic intestinal pseudo-obstruction and bladder weakness. By employing biochemical, structural, cellular, and stem cell methodologies, the researchers hope to develop targeted therapies that address the unique disease mechanisms associated with different mutations. This approach is designed to improve patient outcomes by tailoring treatments to the specific genetic variants present in individuals.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals diagnosed with visceral myopathy, particularly those with mutations in the ACTG2 gene.

Not a fit: Patients without visceral myopathy or those whose condition is not linked to ACTG2 mutations may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new, more effective treatments for patients suffering from visceral myopathy.

How similar studies have performed: While the study of actin mutations is established, the specific focus on ACTG2 and its role in visceral myopathy is relatively novel and has not been extensively tested in prior research.

Where this research is happening

Philadelphia, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.